Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

The use of dendritic cells in cancer therapy

Dendritic cells for specific cancer immunotherapy

Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration

In vitro induction of a bladder cancer-specific T-cell response by mRNA-transfected dendritic cells

Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein

Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide

Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects